|Bid||42.69 x 900|
|Ask||42.70 x 4000|
|Day's Range||42.19 - 42.74|
|52 Week Range||34.32 - 46.47|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||22.86|
|Earnings Date||Apr 29, 2019 - May 3, 2019|
|Forward Dividend & Yield||1.44 (3.43%)|
|1y Target Est||44.46|
“Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system,” said Andreas Penk, M.D., regional president, Oncology International Developed Markets at Pfizer.
BALTIMORE, Feb. 19, 2019 /PRNewswire/ -- Gliknik Inc. today announced that it will receive a $15 million milestone payment from Pfizer Inc. (PFE) following the start of a Phase I clinical trial of Pfizer drug candidate PF-06755347, previously known as GL-2045, for the potential treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disorder. Gliknik and Pfizer entered into an exclusive worldwide licensing agreement in 2013.
A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday. The drug was being tested in patients who had already used three different classes of painkillers but had not experienced enough relief or were intolerant to those treatments. Tanezumab belongs to a category of pain medications that target the nerve growth factor, a protein involved in the growth of nerve cells.
Pfizer and Eli Lilly said on Tuesday that a higher dose of their non-opioid drug tanezumab succeeded in reducing chronic low back pain in patients in a late-stage clinical study. However, a lower dose ...
NEW YORK and INDIANAPOLIS, Feb. 19, 2019 /PRNewswire/ -- Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In this study, CLBP was defined as low back pain that had persisted for more than three consecutive months. On average, they had CLBP for 10 years, and they reported a significant impact of their pain on their ability to function in everyday life.
Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Pfizer Inc NYSE:PFEView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for PFE with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding PFE totaled $11.79 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. PFE credit default swap spreads are near the lowest level of the last one year and indicate improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Drug makers are seeing ever-smaller returns from their research & development efforts, a study shows. That’s one reason 2019 is likely to be a big year for drug mergers.
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed. Merck on Monday released interim data from the trial, saying the combination reduced the risk of death by 47 percent compared with Sutent.
Announcement: Moody's announces completion of a periodic review of ratings of Pfizer Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Pfizer Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Bristol-Myers Squibb could still be in play, an analyst said Friday, suggesting Johnson and Johnson, Pfizer or Amgen could make a bid. That would break up Bristol's takeover of Celgene.
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth drivers On its fourth-quarter earnings conference call, GlaxoSmithKline (GSK) highlighted the prioritization of R&D (research and development)
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson. The drug, tested on early stage prostate cancer that does not respond to hormonal therapy, was shown to be safe to use with only fatigue as the most serious side effect, Bayer said on Thursday, citing a phase-three study that could be decisive for regulatory approval. Given the cancer is not yet spreading and patients are still relatively unburdened by the disease, a drug's tolerability is a key concern for the generally elderly men taking it, said Robert LaCaze, Bayer's head of oncology.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 13) Abbott Laboratories (NYSE: ABT ) Ionis Pharmaceuticals ...
Pfizer holds a lead in the erectile dysfunction market even as generics erode sales of its once-blockbuster male libido treatment, Viagra. According to GoodRx, 65 percent of ED prescriptions filled from Dec. 1, 2018, to Jan. 31, 2019, were for Viagra or its generic version. Pfizer has been able to maintain a significant share in the erectile dysfunction market thanks in part to launching its own generic version of the blue, diamond-shaped pill.
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.
How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)Expense guidance for fiscal 2019 In its fourth-quarter earnings investor presentation, Pfizer (PFE) guided for adjusted cost of sales as a percentage of revenues of 20.8% to
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)Growth drivers In its fourth-quarter earnings conference call, Pfizer (PFE) highlighted innovative health drugs such as Ibrance, Xtandi, Eliquis, and Xeljanz, its vaccines
How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)Dividend projections Pfizer (PFE) and Eli Lilly (LLY) reported dividends per share of $1.36 and $2.25 in fiscal 2018, respectively. Analysts expect Pfizer’s dividend per share